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Letter to the Editor: New Observations 
 
Chronic pain affects 60-85% of people with Parkinson’s disease (PD) and has a strong 
negative effect on quality of life.1 Genetic factors are significantly associated with a variety 
of chronic pain conditions.2 Identifying additional genetic modifiers of pain in people with 
Parkinson’s is of high scientific and clinical interest and could open avenues for novel 
treatments. Here, we report the results of the first Genome Wide Association Study (GWAS) 
of pain in PD.  
 
Parkinson’s patients were recruited from the UK Parkinson's Pain Study which included 
patients from the Tracking Parkinson’s and the Oxford Parkinson’s Disease Centre (OPDC) 
cohorts.  The clinical assessment of pain in these patients has been previously reported.1 PD 
patients were stratified into two groups that represented individuals with no/low pain (McGill 
score < 3 and VAS severity < 2), and high pain (McGill Score >= 3 and VAS severity >= 2).  
 
DNA extracted from each sample was genotyped using either the Illumina Human 
ExomeCore-12 v1.1 array (Tracking Parkinson’s) or the InfiniumCoreExome-24 v1.1 
(OPDC). Genotype data from both cohorts underwent the same conventional processing, QC 
and imputation procedures as described elsewhere.3  
 
We performed a GWAS of 6,655,232 autosomal SNPs that compared a total of 898 patients 
with Parkinson’s who were classed as suffering high levels of pain to 420 Parkinson’s 
patients who were not experiencing pain. After including covariates for age, gender and 
ancestry in the association analysis there was no evidence of genomic inflation attributable to 
population stratification (λ=1.00).  
 
This analysis identified 2 SNPs (rs11563208 and rs12465950) that were associated with pain 
in PD at genome wide significance (p=1.45E-09; O.R. 1.78 and p=9.30E-09; O.R. 1.71 
respectively) (Figure 1). The genotypes of these SNPs were strongly correlated (r2=0.85) and 
are located at the gene encoding the human transient receptor potential cation channel, 
subfamily M, member 8 (TRPM8) on chromosome 2q37.1, with rs11563208 being a 
synonymous variant located within exon 22 and rs120465950 intronic. SNPs within TRPM8 
are established risk factors for migraine and headaches at genome-wide significance.4 Using 
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rs10166942 as a marker for the genetic association with migraine,4 conditional association 
analysis of pain in PD confirmed the strong association at rs11563208 (OR=1.81, p=4.2E-
08), supporting its independence to the genetic risk for migraine. An assessment of published 
GWAS data did not identify the lead SNPs at the TRPM8 locus to be associated with any 
other pain phenotype.5  
 
TRPM8 has several reported functions, most notably as a cold/menthol thermoreceptor and is 
expressed in dorsal horn neurons.6 Genetic variants at this locus are also strongly associated 
with migraine susceptibility,4 however, we note that our conditional analysis implies that 
these variants are independent of those associated with pain in PD in our analysis. This 
suggests the role of TRPM8 in PD pain may be different mechanistically to that of migraine.  
TRPM8 has been previously linked to chronic pain in animal models and research is ongoing 
to identify compounds that effectively target TRPM8, with numerous antagonists being 
patented by pharmaceutical companies.6 Interestingly, cannabinoid ligands, compounds 
which have demonstrated efficacy as analgesic agents, have been shown to antagonise the 
TRPM8 receptor.7 Indeed some  authors have termed TRPM8 and other related TRP channels 
as ionotropic cannabinoid receptors, suggesting that cannabinoids may be worth pursuing as 
treatments for PD pain.  
 
In conclusion, we report the first genome-wide significant evidence for association with pain 
susceptibility in PD, which implicates the gene TRPM8. The large body of evidence 
implicating this gene with migraine and chronic pain has already resulted in this gene being a 
pharmacologic target, and together with its known relationship with cannabinoids, opens 
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Figure 1: Manhattan plot of -log10 SNP p-values from a meta-analysis of high pain (n=898) 
vs low pain (n=420). Red and blue lines represent the thresholds for genome-wide (P<5E-08) 
and suggestive (P<1E-06) significance respectively.  
 
